Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Drug resistance remains a significant challenge in the treatment of colorectal cancer (CRC). In recent years, the emerging field of ferroptosis, a unique form of regulated cell death characterized by iron-dependent lipid peroxidation, has offered new insights and potential therapeutic strategies for overcoming drug resistance in CRC. This review examines the role of ferroptosis in CRC and its impact on drug resistance. It highlights the distinctive features and advantages of ferroptosis compared to other cell death pathways, such as apoptosis and necrosis. Furthermore, the review discusses current research advances in the field, including novel treatment approaches that target ferroptosis. These approaches involve the use of ferroptosis inducers, interventions in iron metabolism and lipid peroxidation, and combination therapies to enhance the efficacy of ferroptosis. The review also explores the potential of immunotherapy in modulating ferroptosis as a therapeutic strategy. Additionally, it evaluates the strengths and limitations of targeting ferroptosis, such as its selectivity, low side effects, and potential to overcome resistance, as well as challenges related to treatment specificity and drug development. Looking to the future, this review discusses the prospects of ferroptosis-based therapies in CRC, emphasizing the importance of further research to elucidate the interaction between ferroptosis and drug resistance. It proposes future directions for more effective treatment strategies, including the development of new therapeutic approaches, combination therapies, and integration with emerging fields such as precision medicine. In conclusion, harnessing ferroptosis represents a promising avenue for overcoming drug resistance in CRC. Continued research efforts in this field are crucial for optimizing therapeutic outcomes and providing hope for CRC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, changes in drug metabolism contribute to resistance, with CRC cells increasing the inactivation or degradation of drugs through upregulated expression of enzymes like glutathione S-transferases (GSTs), uridine 5′-diphospho-glucuronosyltransferases (UGTs), and cytochrome P450 (CYP) enzymes [46,47].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other ferroptosis-based strategies could involve interventions in iron metabolism and lipid peroxidation [46].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: MiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2
Fan, H., Ai, R., Mu, S., Niu, X., Guo, Z., & Liu, L. (2022) · Bioengineered · doi:10.1080/21655979.2022.2054194 · Cited by 62
RetractedChen, Z., Zhu, Y., Dong, Y., Zhang, P., Han, X., Jin, J., & Ma, X. (2017) · Clinical Science · doi:10.1042/cs20171069 · Cited by 58
RetractedFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 1×
“The LIP is a critical reservoir of Fe 2+ that fuels the Fenton reaction and subsequently drives lipid peroxidation, a key event in ferroptosis [67].”
BackgroundFerroptosis: mechanisms, biology and role in disease
Jiang, X., Stockwell, B. R., & Conrad, M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00324-8 · Cited by 7,505
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293 · cited 3×
“In nonenzymatic lipid peroxidation, the conversion of polyunsaturated fatty acids (PUFAs) into acyl-CoA is facilitated by acyl-CoA synthetase long-chain family member 4 (ACSL4), which ligates PUFAs with coenzyme A (CoA) [59].”
BackgroundThe CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1705-2 · Cited by 3,703
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Ferroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1170-y · Cited by 2,880
Targeting Ferroptosis to Iron Out Cancer
Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.002 · Cited by 2,478
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“For example, mutations in the KRAS gene are associated with resistance to anti-EGFR antibodies like cetuximab and panitumumab in CRC patients [15–17].”
BackgroundTwo to tango: Regulation of Mammalian iron metabolism
Hentze, M. W., Muckenthaler, M. U., Galy, B., & Camaschella, C. (2010) · Cell · doi:10.1016/j.cell.2010.06.028 · Cited by 2,120 · cited 1×
“TFR facilitates the uptake of iron by binding to transferrin, which transports Fe into the cell via receptor-mediated endocytosis [63].”
BackgroundFerroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
Ferroptosis is an autophagic cell death process
Gao, M., Monian, P., Pan, Q., Zhang, W., Xiang, J., & Jiang, X. (2016) · Cell Research · doi:10.1038/cr.2016.95 · Cited by 1,899
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 1×
“The abnormal expression or function of drug transport proteins, such as ATP-binding cassette (ABC) transporters, can also lead to reduced intracellular drug accumulation and confer resistance to various anticancer drugs [22,23].”
BackgroundMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 1×
“Furthermore, the TME can elicit innate resistance to targeted therapies [50].”
BackgroundIron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621 · cited 1×
“…intracellular iron and preventing it from participating The availability of intracellular GSH, which is regulated by the cystine/glutamate antiporter (xCT) system and glutamate–cysteine ligase, influences GPX4 activity and determines the susceptibility to ferroptosis [57]. the Fenton reaction [64].”
BackgroundSeiler, A., Schneider, M., Förster, H., Roth, S., Wirth, E. K., Culmsee, C., Plesnila, N., Kremmer, E., Rådmark, O., Wurst, W., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.005 · Cited by 1,470
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Mashouri, L., Yousefi, H., Aref, A. R., Ahadi, A. M., Molaei, F., & Alahari, S. K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0991-5 · Cited by 1,363
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance
Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01530-y · Cited by 1,332
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
Friedmann Angeli, J. P., Krysko, D. V., & Conrad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0149-1 · Cited by 1,259
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.350 · Cited by 1,204
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0338 · Cited by 1,047
Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death
Dixon, S. J., Winter, G. E., Musavi, L. S., Lee, E. D., Snijder, B., Rebsamen, M., Superti-Furga, G., & Stockwell, B. R. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00245 · Cited by 1,043 · cited 2×
“Therefore, the regulation of ACSL4 and LPCATs plays a critical role in determining the sensitivity to ferroptosis [69].”
BackgroundCAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Zhang, H., Deng, T., Liu, R., Ning, T., Yang, H., Liu, D., Zhang, Q., Lin, D., Ge, S., Bai, M., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01168-8 · Cited by 1,016
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J., Zhong, M., Yuan, H., Zhang, L., Billiar, T. R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.055 · Cited by 952 · cited 1×
“On a specific gene and protein level, certain studies emphasize the roles of particular factors in CRC, such as KRAS mutations, Nodal, MT1G, SFRS9, and p53 [82–86].”
BackgroundPEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals
Wenzel, S. E., Tyurina, Y. Y., Zhao, J., St. Croix, C. M., Dar, H. H., Mao, G., Tyurin, V. A., Anthonymuthu, T. S., Kapralov, A. A., Amoscato, A. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.044 · Cited by 950
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898 · cited 1×
“Venook et al. conducted a randomized clinical trial that highlighted the adverse impact of drug resistance on overall survival and the quality of life in patients with KRAS wild-type advanced or metastatic CRC [10].”
BackgroundOhgami, R. S., Campagna, D. R., Greer, E. L., Antiochos, B., McDonald, A., Chen, J., Sharp, J. J., Fujiwara, Y., Barker, J. E., & Fleming, M. D. (2005) · Nature Genetics · doi:10.1038/ng1658 · Cited by 775
Emerging Strategies of Cancer Therapy Based on Ferroptosis
Shen, Z., Song, J., Yung, B. C., Zhou, Z., Wu, A., & Chen, X. (2018) · Advanced Materials · doi:10.1002/adma.201704007 · Cited by 740
Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis
Zou, Y., Li, H., Graham, E. T., Deik, A. A., Eaton, J. K., Wang, W., Sandoval-Gomez, G., Clish, C. B., Doench, J. G., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0472-6 · Cited by 734
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
Sui, X., Zhang, R., Liu, S., Duan, T., Zhai, L., Zhang, M., Han, X., Xiang, Y., Huang, X., Lin, H., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01371 · Cited by 703
Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28574 · Cited by 703
Self-citationGPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues
Maiorino, M., Conrad, M., & Ursini, F. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7115 · Cited by 703
The calcium–cancer signalling nexus
Monteith, G. R., Prevarskaya, N., & Roberts-Thomson, S. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.18 · Cited by 635
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 589
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Adaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433 · cited 1×
“Moreover, abnormalities in DNA repair pathways like mismatch repair (MMR) and homologous recombination (HR) can lead to genomic instability and resistance to DNA-damaging agents [34–36].”
BackgroundChen, P., Li, X., Zhang, R., Liu, S., Xiang, Y., Zhang, M., Chen, X., Pan, T., Yan, L., Feng, J., et al. (2020) · Theranostics · doi:10.7150/thno.44705 · Cited by 403
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D'Alessandro, A., Culp-Hill, R., d'Almeida, A., Joshi, S. K., Rosenberg, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 378
Hong, T., Lei, G., Chen, X., Li, H., Zhang, X., Wu, N., Zhao, Y., Zhang, Y., & Wang, J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101928 · Cited by 373
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression
Wu, Y., Zhang, S., Gong, X., Tam, S., Xiao, D., Liu, S., & Tao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01157-x · Cited by 344
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Lin, J.-F., Hu, P.-S., Wang, Y.-Y., Tan, Y.-T., Yu, K., Liao, K., Wu, Q.-N., Li, T., Meng, Q., Lin, J.-Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00889-0 · Cited by 330
Recent progress in ferroptosis: inducers and inhibitors
Du, Y., & Guo, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01297-7 · Cited by 322
Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04367-3 · Cited by 300 · cited 1×
“…for ferroptosis offers innovative strategies for sensitizing cancer cells to ferroptosis-inducing agents, with a focus on KRAS-mutant CRC. Combining cetuximab with RSL3 enhances ferroptosis in KRAS-mutant CRC cells, providing a strategy to overcome drug resistance in this specific subgroup [120].”
BackgroundFu, D., Wang, C., Yu, L., & Yu, R. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00271-y · Cited by 283
Narayanankutty, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666190618123846 · Cited by 255
Gai, C., Liu, C., Wu, X., Yu, M., Zheng, J., Zhang, W., Lv, S., & Li, W. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02939-3 · Cited by 243
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Hafezi, S., & Rahmani, M. (2021) · Cancers · doi:10.3390/cancers13061292 · Cited by 234
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Self-citationZhang, Q., Deng, T., Zhang, H., Zuo, D., Zhu, Q., Bai, M., Liu, R., Ning, T., Zhang, L., Yu, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202203357 · Cited by 229
Yu, H., Yang, C., Jian, L., Guo, S., Chen, R., Li, K., Qu, F., Tao, K., Fu, Y., Luo, F., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7189 · Cited by 222
Chakrabarty, S., Radjendirane, V., Appelman, H. D., & Varani, J. (2003) · PubMed · Cited by 208
Targeting ferroptosis in breast cancer
Li, Z., Chen, L., Chen, C., Zhou, Y., Hu, D., Yang, J., Chen, Y., Zhuo, W., Mao, M., Zhang, X., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00230-3 · Cited by 200
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Du, J., Wang, X., Li, Y., Ren, X., Zhou, Y., Hu, W., Zhou, C., Jing, Q., Yang, C., Wang, L., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03996-y · Cited by 197
Cytochrome P450 CYP1B1 protein expression:
McFadyen, M. C. E., McLeod, H. L., Jackson, F. C., Melvin, W. T., Doehmer, J., & Murray, G. I. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00643-8 · Cited by 188
Hu, Q., Wei, W., Wu, D., Huang, F., Li, M., Li, W., Yin, J., Peng, Y., Lu, Y., Zhao, Q., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.810327 · Cited by 187
Chaudhary, N., Choudhary, B. S., Shah, S. G., Khapare, N., Dwivedi, N., Gaikwad, A., Joshi, N., Raichanna, J., Basu, S., Gurjar, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33711 · Cited by 185 · cited 1×
“FAM98A overexpression in CRC tissues has been linked to drug resistance, with metformin demonstrating potential in reversing FAM98A-mediated 5-FU resistance [108].”
BackgroundYang, C., Zhang, Y., Lin, S., Liu, Y., & Li, W. (2021) · Aging · doi:10.18632/aging.202774 · Cited by 174 · cited 1×
“KIF20A, associated with oxaliplatin resistance, becomes a potential target for sensitizing CRC cells to this drug [107].”
BackgroundSong, X., Wang, X., Liu, Z., & Yu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.597434 · Cited by 172
Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01070 · Cited by 170
Zeng, K., Li, W., Wang, Y., Zhang, Z., Zhang, L., Zhang, W., Xing, Y., & Zhou, C. (2023) · Advanced Science · doi:10.1002/advs.202301088 · Cited by 168
Chen, H., Qi, Q., Wu, N., Wang, Y., Feng, Q., Jin, R., & Jiang, L. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102426 · Cited by 163
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160 · cited 1×
“The mechanisms underlying drug resistance in CRC are complex and multifactorial, encompassing genetic alterations, activation of survival signaling pathways, and disruptions in drug metabolism and efflux [4,5].”
BackgroundXia, Y., Liu, S., Li, C., Ai, Z., Shen, W., Ren, W., & Yang, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03194-2 · Cited by 145
Landriscina, M., Laudiero, G., Maddalena, F., Amoroso, M. R., Piscazzi, A., Cozzolino, F., Monti, M., Garbi, C., Fersini, A., Pucci, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1256 · Cited by 143
CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer
Chen, C., Yang, Y., Guo, Y., He, J., Chen, Z., Qiu, S., Zhang, Y., Ding, H., Pan, J., & Pan, Y.-L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05803-2 · Cited by 140
Progress in Understanding Ferroptosis and Challenges in Its Targeting for Therapeutic Benefit
Zou, Y., & Schreiber, S. L. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.03.015 · Cited by 137
Sun, Y., Qiao, Y., Liu, Y., Zhou, J., Wang, X., Zheng, H., Xu, Z., Zhang, J., Zhou, Y., Qian, L., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101977 · Cited by 131
Wei, Z., Hang, S., Ocansey, D. K. W., Zhang, Z., Wang, B., Zhang, X., & Mao, F. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01951-x · Cited by 128
Lee, J., You, J. H., Shin, D., & Roh, J.-L. (2020) · Theranostics · doi:10.7150/thno.46903 · Cited by 126
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Targeting Bcl-2 for cancer therapy
Zhang, L., Lu, Z., & Zhao, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188569 · Cited by 118
Shao, Y., Jia, H., Huang, L., Li, S., Wang, C., Aikemu, B., Yang, G., Hong, H., Yang, X. Y., Zhang, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.711776 · Cited by 115
TIGAR drives colorectal cancer ferroptosis resistance through ROS/AMPK/SCD1 pathway
Liu, M.-Y., Li, H., Wang, X., Ran, X., Li, X., Ma, Y.-J., Wang, M., & Zhang, H.-S. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.002 · Cited by 113
Shen, D., Luo, J., Chen, L., Ma, W., Mao, X., Zhang, Y., Zheng, J., Wang, Y., Wan, J., Wang, S., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215919 · Cited by 108
The role of glucuronidation in drug resistance
Mazerska, Z., Mróz, A., Pawłowska, M., & Augustin, E. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.009 · Cited by 107
Wang, T., Chen, Z., Zhu, Y., Pan, Q., Liu, Y., Qi, X., Jin, L., Jin, J., Ma, X., & Hua, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.590364 · Cited by 104
Insights into the novel function of system Xc- in regulated cell death.
Tu, H., Tang, L.-J., Luo, X.-J., Ai, K.-L., & Peng, J. (2021) · PubMed · doi:10.26355/eurrev_202102_24876 · Cited by 102
Han, Y., Gao, X., Wu, N., Jin, Y., Zhou, H., Wang, W., Liu, H., Chu, Y., Cao, J., Jiang, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05192-y · Cited by 101
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94 · cited 1×
“Drug resistance presents a pervasive challenge in colorectal cancer (CRC) treatment [1,2].”
BackgroundSun, R., Lin, Z., Wang, X., Liu, L., Huo, M., Zhang, R., Lin, J., Xiao, C., Li, Y., Zhu, W., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02493-0 · Cited by 88
mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential
Lei, G., Zhuang, L., & Gan, B. (2021) · BioEssays · doi:10.1002/bies.202100093 · Cited by 87
Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy
Chen, Y., Yang, Z., Wang, S., Ma, Q., Li, L., Wu, X., Guo, Q., Tao, L., & Shen, X. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202150 · Cited by 87
Rashba-Step, J., Tatoyan, A., Duncan, R., Ann, D. K., Pushpa-Rehka, T. R., & Sevanian, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0134 · Cited by 84
Lv, Y., Tang, W., Chang, W., Chang, W., Xu, Y., Qi, L., Ji, M., Feng, Q., Xu, J., & He, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.74985 · Cited by 83
Sorcin Induces a Drug-Resistant Phenotype in Human Colorectal Cancer by Modulating Ca2+ Homeostasis
Maddalena, F., Laudiero, G., Piscazzi, A., Secondo, A., Scorziello, A., Lombardi, V., Matassa, D. S., Fersini, A., Neri, V., Esposito, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2172 · Cited by 81
Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79
Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents
Li, L., Shi, Q., Su, C.-Y., Shih, C. C.-Y., & Lee, K. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.034 · Cited by 76
Apatinib Promotes Ferroptosis in Colorectal Cancer Cells by Targeting ELOVL6/ACSL4 Signaling
Tian, X., Li, S., & Ge, G. (2021) · Cancer Management and Research · doi:10.2147/cmar.s274631 · Cited by 75
The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
Pashirzad, M., Khorasanian, R., Fard, M. M., Arjmand, M., Langari, H., Khazaei, M., Soleimanpour, S., Rezayi, M., Ferns, G. A., Hassanian, S. M., et al. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666211103113339 · Cited by 74
Kadel, D., Zhang, Y., Sun, H.-R., Zhao, Y., Dong, Q.-Z., & Qin, L.-X. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09461-z · Cited by 63
Grignano, É., Cantero-Aguilar, L., Tuerdi, Z., Chabane, T., Vazquez, R., Johnson, N., Zerbit, J., Decroocq, J., Birsen, R., Fontenay, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01371-8 · Cited by 63
Battista, T., Fiorillo, A., Chiarini, V., Genovese, I., Ilari, A., & Colotti, G. (2020) · Cancers · doi:10.3390/cancers12040887 · Cited by 62
Prevete, N., Liotti, F., Illiano, A., Amoresano, A., Pucci, P., de Paulis, A., & Melillo, R. M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1293213 · Cited by 61
Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species
Tang, F., Zhou, L.-Y., Li, P., Jiao, L., Chen, K., Guo, Y., Ding, X., He, S., Dong, B., Xu, R., et al. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01382-4 · Cited by 60
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 58
Qiao, C., Wang, H., Guan, Q., Wei, M., & Li, Z. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.09.002 · Cited by 57
Du, S., Zeng, F., Sun, H., Liu, Y., Han, P., Zhang, B., Xue, W., Deng, G., Yin, M., & Cui, B. (2022) · Bioengineered · doi:10.1080/21655979.2021.2017627 · Cited by 56
Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer
Wang, T., Ning, K., Lu, T., & Hua, D. (2016) · Oncology Reports · doi:10.3892/or.2016.5322 · Cited by 49
Wu, T., Wan, J., Qu, X., Xia, K., Wang, F., Zhang, Z., Yang, M., Wu, X., Gao, R., Yuan, X., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05756-6 · Cited by 49
Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan, H. Y., Talty, R., Jain, A., Cai, Y. A., Zheng, J., Shen, X., Muca, E., Paty, P. B., Bosenberg, M., Khan, S. A., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102699 · Cited by 48
Yang, Y., Lin, Z., Han, Z., Wu, Z., Hua, J., Zhong, R. M., Zhao, R., Ran, H., Qu, K., Huang, H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00659-x · Cited by 46
Wang, R., Xing, R., Su, Q., Yin, H., Wu, D., Lv, C., & Yan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683589 · Cited by 45
Exosomal Noncoding RNAs and Tumor Drug Resistance
Guo, C., Liu, J., Zhou, Q., Song, J., Zhang, Z., Li, Z., Wang, G., Yuan, W., & Sun, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0032 · Cited by 45
Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy
Gu, X., Liu, Y., Dai, X., Yang, Y., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1137107 · Cited by 43
Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2023) · Antioxidants · doi:10.3390/antiox12040894 · Cited by 39
Hamad, M. A., Mohammed, A. K., Hachim, M. Y., Mukhopadhy, D., Khalique, A., Laham, A. J., Dhaiban, S., Bajbouj, K., & Taneera, J. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111462 · Cited by 39
CircRNA circSTIL inhibits ferroptosis in colorectal cancer via miR ‐431/ SLC7A11 axis
Li, Q., Li, K., Guo, Q., & Yang, T. (2023) · Environmental Toxicology · doi:10.1002/tox.23670 · Cited by 39
NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
Yang, G., Huang, L., Jia, H., Aikemu, B., Zhang, S., Shao, Y., Hong, H., Yesseyeva, G., Wang, C., Li, S., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01962-8 · Cited by 35
TrpC5 regulates differentiation through the Ca2+/Wnt5a signalling pathway in colorectal cancer
Chen, Z., Tang, C., Zhu, Y., Xie, M., He, D., Pan, Q., Zhang, P., Hua, D., Wang, T., Jin, L., et al. (2016) · Clinical Science · doi:10.1042/cs20160759 · Cited by 34
Lv, Y., Tang, W., Zhang, Z., Lin, Q., Luo, Y., Zheng, P., Li, K., Jia, X., YuZhi, P., Ji, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02284-z · Cited by 32
Mu, M., Zhang, Q., Zhao, C., Li, X., Chen, Z., Sun, X., & Yu, J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00648-5 · Cited by 32
Peng, B., Peng, J., Kang, F., Zhang, W.-Q., Peng, E., & He, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881447 · Cited by 27
Zhou, B., Mai, Z., Ye, Y., Song, Y., Zhang, M., Yang, X., Xia, W. G., & Qiu, X. (2022) · Human Cell · doi:10.1007/s13577-022-00775-5 · Cited by 25
Loss of SLC46A1 decreases tumor iron content in hepatocellular carcinoma
Wang, D., Wu, H., Yang, J., Li, M., Ling, C., Gao, Z., Lu, H., Shen, H., & Tang, Y. (2022) · Hepatology Communications · doi:10.1002/hep4.2031 · Cited by 25
Zhang, W., Luo, M., Xiong, B., & Liu, X. (2022) · Journal of Oncology · doi:10.1155/2022/4000617 · Cited by 25
Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis
Wu, J., Liu, C., Wang, T., Liu, H., & Wei, B. (2023) · Immunology · doi:10.1111/imm.13683 · Cited by 24
Transforming Lipoxygenases: PE-Specific Enzymes in Disguise
Ye, L. F., & Stockwell, B. R. (2017) · Cell · doi:10.1016/j.cell.2017.10.006 · Cited by 23
Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
Zahreddine, H. A., & Borden, K. L. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1370 · Cited by 21
Yu, Z., Tong, S., Wang, C., Wu, Z., Ye, Y., Wang, S., & Jiang, K. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1001994 · Cited by 19
Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway
Liu, D., Jiang, H., Kang, Z., & Guan, M. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117338 · Cited by 14
Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro
Hou, Y., Wang, Y., Wang, X.-C., Liu, Y., Zhang, C.-Z., Chen, Z., Zhang, Z., Wang, W., & Kong, D. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa076 · Cited by 9
Shen, F., Jiang, G., Philips, S., Gardner, L., Xue, G. R., Cantor, E., Ly, R. C., Osei, W., Wu, X., Dang, C. T., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2431 · Cited by 7
A step closer to combating acquired resistance in CRC
Hutchinson, L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.128 · Cited by 2
Cited by
Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential
Sun, D., Wang, L., Wu, Y., Yu, Y., Yao, Y., Yang, H., & Hao, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545339 · Cited by 110
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“…in drug metabolism contribute to resistance, with CRC cells increasing the inactivation or degradation of drugs through upregulated expression of enzymes like glutathione S-transferases (GSTs), uridine 5 ′ -diphospho-glucuronosyltransferases (UGTs), and cytochrome P450 (CYP) enzymes [46,47].”
Non-coding RNA: A key regulator in the Glutathione-GPX4 pathway of ferroptosis
Hussain, M. S., Gupta, G., Shahwan, M. J., Bansal, P., Kaur, H., Deorari, M., Pant, K., Ali, H., Singh, S. K., Allam, V. S. R. R., et al. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.05.007 · Cited by 51
Ferroptosis and immunosenescence in colorectal cancer
Wang, Y., Cao, X., Yang, C., Fan, J., Zhang, X., Wu, X., Guo, W., Sun, S., Liu, M., Zhang, L., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.003 · Cited by 52
Cell death signaling and immune regulation: new perspectives on targeted therapy for sepsis
Wu, H., Cui, J., Huang, J., Feng, Y., Zhao, J., Zhu, Y., Deng, X., Li, X., Zhang, W., & Wang, C. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00784-w · Cited by 34
Metadata
- Authors
- Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Corresponding author
- Cheng, Xiaofei
- Liu, Fanlong
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-10-30
- Volume
- 15
- Issue
- 21
- Pages
- 5209
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10649072
- OpenAlex
- W4388017931
- Cited by
- 44
- References
- 137
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 12
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- ferroptosis, colorectal cancer, drug resistance, iron metabolism, lipid peroxidation, ferroptosis inducers, combination therapy, immunotherapy, targeted therapy, precision medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.